首页> 外文期刊>American journal of therapeutics >Prevalence of use of cardiovascular drugs in 499 patients with suspected coronary artery disease at time of hospitalization for coronary angiography and in 357 patients with obstructive coronary artery disease documented by coronary angiography.
【24h】

Prevalence of use of cardiovascular drugs in 499 patients with suspected coronary artery disease at time of hospitalization for coronary angiography and in 357 patients with obstructive coronary artery disease documented by coronary angiography.

机译:499例在住院时进行冠状动脉造影的可疑冠状动脉疾病患者和357例通过冠状动脉造影所记录的梗阻性冠状动脉疾病的心血管药物使用率。

获取原文
获取原文并翻译 | 示例
           

摘要

In a prospective study of 499 patients with suspected coronary artery disease (CAD) hospitalized for coronary angiography, the prevalence of use of cardiovascular drugs at hospital admission was 80% for antiplatelet drugs, 66% for beta blockers, 55% for angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), 65% for lipid-lowering drugs, 24% for calcium channel blockers (CCBs), and 16% for nitrates. In 357 patients with obstructive CAD diagnosed by coronary angiography, the prevalence of use of these drugs at hospital discharge was 100% for antiplatelet drugs, 97% for beta blockers, 91% for ACE inhibitors or ARBs, 98% for lipid-lowering drugs, 17% for CCBs, and 27% for nitrates. Obstructive CAD was significantly more prevalent in men (P < 0.025), in cigarette smokers (P < 0.01), and in patients with hypertension, diabetes, or hypercholesterolemia (P < 0.001). Age, race, body mass index, and neck circumference were not significantly different for patients with versus without obstructive CAD.
机译:在一项对499名因冠脉造影而住院的疑似冠心病(CAD)患者的前瞻性研究中,入院时使用抗心血管疾病药物的比例为:抗血小板药物占80%,β受体阻滞剂占66%,血管紧张素转化酶占55%。 (ACE)抑制剂或血管紧张素受体阻滞剂(ARB),降脂药物占65%,钙通道阻滞剂(CCB)占24%,硝酸盐占16%。在357例通过冠状动脉造影诊断为阻塞性CAD的患者中,出院时使用这些药物的普遍性是:抗血小板药物为100%,β受体阻滞剂为97%,ACEI或ARB为91%,降脂药物为98%, CCB为17%,硝酸盐为27%。阻塞性CAD在男性(P <0.025),吸烟者(P <0.01)以及高血压,糖尿病或高胆固醇血症患者(P <0.001)中更为普遍。有或没有阻塞性CAD的患者的年龄,种族,体重指数和颈围均无显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号